CONTACT US
TO GET MORE
INFORMATION

IMPORTANT SAFETY INFORMATION

ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

The most common adverse reactions (≥1%) for ZORYVE cream 0.15% for atopic dermatitis include headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).

The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for plaque psoriasis include headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).

Please see full Prescribing Information for ZORYVE cream and full Prescribing Information for ZORYVE foam.

INDICATIONS

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.

References: 1. ZORYVE^® foam. Prescribing information. Arcutis Biotherapeutics, Inc; 2025. 2. ZORYVE^® cream. Prescribing information. Arcutis Biotherapeutics, Inc; 2024. 3. Osborne DW. Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products. J Cosmet Dermatol. 2011;10:325–329. 4. Osborne DW, Musakhanian J. Skin penetration and permeation properties of Transcutol^® - neat or diluted mixtures. AAPS PharmSciTech. 2018;19(8):3512–3533. 5. Berk D, Osborne DW. Krafft temperature of surfactants in vehicles for roflumilast and pimecrolimus cream and effects on skin tolerability. Poster presented at: The Society for Investigative Dermatology Annual Meeting; May 18–22, 2022; Portland, OR. 6. Björklund S, Pham QD, Jensen LB, et al. The effects of polar excipients transcutol and dexpanthenol on molecular mobility, permeability, and electrical impedance of the skin barrier. J Colloid Interface Sci. 2016;479:207–220. 7. Data on File. Arcutis Biotherapeutics, Inc.

ICD-10=International Classification of Diseases, Tenth Revision; IGA=Investigator Global Assessment.

References: 1. ZORYVE^® foam. Prescribing information. Arcutis Biotherapeutics, Inc; 2025. 2. ZORYVE^® cream. Prescribing information. Arcutis Biotherapeutics, Inc; 2024. 3. CMS.gov. 2025 ICD-10-CM. Centers for Medicare & Medicaid Services. Updated January 17, 2025. Accessed June 9, 2025. https://www.cms.gov/medicare/coding-billing/icd-10-codes 4. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432-470. 5. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1-e20. 6. Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91(3):185-190.

References: 1. ZORYVE^® foam. Prescribing information. Arcutis Biotherapeutics, Inc; 2025. 2. ZORYVE^® cream. Prescribing information. Arcutis Biotherapeutics, Inc; 2024.

References: 1. ZORYVE^® foam. Prescribing information. Arcutis Biotherapeutics, Inc; 2025. 2. ZORYVE^® cream. Prescribing information. Arcutis Biotherapeutics, Inc; 2024.